Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on October 24, 2025. The report discloses a significant clinical milestone under Item 8.01 (Other Events) regarding the Company's nPulse Cardiac Surgical System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial event and does not contain financial statements or performance data.
Material Changes and Clinical Milestone
- Event: Enrollment of the first patient in the NANOCLAMP AF clinical trial.
- Study Design: Single-arm, prospective multicenter study.
- Objective: To demonstrate the safety and effectiveness of the nPulse Cardiac Surgical System for treating atrial fibrillation during concomitant surgical procedures.
- Location: The first procedure was successfully completed at St. Helena Hospital in St. Helena, California.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the inherent nature of clinical trials. The report incorporates a press release (Exhibit 99.1) detailing the enrollment announcement.
Key Facts for Investor Verification
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study protocols.
- Confirm the timeline for subsequent patient enrollments in the NANOCLAMP AF study.
- Review the Company's most recent 10-Q or 10-K for current financial status, as this 8-K contains no financial data.
- Monitor regulatory communications regarding the nPulse Cardiac Surgical System's path to approval.